The authors of the statement reviewed the small number of published, peer-reviewed studies about the potency of cellular health technologies in managing weight, boosting physical activity, quitting smoking, and controlling high blood pressure, high diabetes and cholesterol. The fact that cellular health technologies haven’t been fully studied doesn’t imply that they are not effective. Self-monitoring is one of the core strategies for changing cardiovascular health behaviors, statement lead writer Lora Burke, professor of nursing and epidemiology, University of Pittsburgh, stated in an AHA news release.Rodney Howell, M.D., Chairman of the MDA Board of Directors. The MDA grant, awarded through the Association’s Venture Philanthropy Program , will support ongoing scientific studies of ACE-031 in males with DMD. The brand new expense will enable Acceleron to gather secure dosing and pharmcodynamic activity info vital to future studies of ACE-031. For more information on these ongoing studies, visit clinicaltrials.gov and query study identifiers NCT01099761 and NCT01239758. MDA is very happy to support Acceleron’s attempts in the fight against Duchenne Muscular Dystrophy, stated Valerie Cwik, M.D., MDA Executive Vice President – Medical and Study Director. Our strategic investment should help Acceleron expedite the next phase of ACE-031 human being clinical trials.